ArticleScientific reports2023
The role of antipsychotics and other drugs on the development and progression of neuroleptic malignant syndrome.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Drug combination choices of 5α-reductase inhibitors and α-blockers in patients with benign prostatic hyperplasia: a study based on the FAERS database.Frontiers in medicine · 2026Article
- Clinical Outcomes and Factors Associated with Neuroleptic Malignant Syndrome in Older Patients: A Case Control Study.Journal of clinical medicine · 2025Article
- Article
- Catatonia in a Possible Case of Moderate Neuroleptic Malignant Syndrome: A Case Report.Reports (MDPI) · 2025Article
- Is Abrupt Withdrawal of Benzodiazepines a Risk Factor for Neuroleptic Malignant Syndrome? A Case Report With Single-Dose Haloperidol.Clinical case reports · 2025Article
- Neuroleptic malignant syndrome in a patient with COVID-19 and the possible role of SARS-CoV-2 in its manifestation: case report and overview of published cases.BMC psychiatry · 2025Review
- Alcohol-Induced Neuroleptic Malignant Syndrome Complicated by Severe Acute Rhabdomyolysis.Cureus · 2025Article
- Disproportionality analysis of taste disorders using the FDA adverse event reporting system and Japanese adverse drug event report databases.Frontiers in pharmacology · 2025Article
- Anesthetic implications of psychotropic medications: a narrative review.Journal of Yeungnam medical science · 2025Article
- Neuroleptic malignant syndrome in Huntington disease.European journal of neurology · 2024Article
- A real-world pharmacovigilance study of neuroleptic malignant syndrome based on FDA adverse event reporting system.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroleptic malignant syndrome (NMS) is a rare but serious and sometimes fatal complication in patients taking antipsychotic drugs, and its underlying mechanism still remains unclear. The pharmacotherapy for psychotic disorders is complicated and often involves a combination of two or more drugs, including drugs other than antipsychotics. In the present study, we used the Japanese Adverse Drug Event Report (JADER) database to broadly investigate the drugs associated with NMS, following their related pathways, as well as the drug-drug interactions (DDIs) in NMS. All analyses were performed using data from the JADER database from April 2004 to May 2022. Single-drug signals were evaluated using the reporting odds ratio (ROR) and proportional reporting ratio (PRR), and drug pathways were investigated using the Kyoto Encyclopedia of Genes and Genomes (KEGG). DDIs were evaluated using the Ω shrinkage measure and Chi-square statistics models. All drugs associated with 20 or more NMS cases in the JADER database exhibited signals for NMS, including non-antipsychotics. Pathways associated with the drugs included the dopaminergic or serotonergic synapses related to antipsychotics. DDIs leading to NMS were confirmed for several drug combinations exhibiting single-drug signals. This study confirmed the significant association of various drugs, including non-psychotics, with NMS and suggested that various pathways related to these drugs may be involved in the progression of NMS. In addition, several combinations of these drugs were found to interact (DDI), increasing the risk of NMS, which suggests that appropriate caution should be taken when administering these drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.